Literature DB >> 27803758

Limitations of low pressure noninvasive ventilation.

João Pedro Abreu Cravo1, Antonio M Esquinas Rodriguez2.   

Abstract

Entities:  

Year:  2016        PMID: 27803758      PMCID: PMC5070441          DOI: 10.4103/1817-1737.191869

Source DB:  PubMed          Journal:  Ann Thorac Med        ISSN: 1998-3557            Impact factor:   2.219


× No keyword cloud information.
Sir, In recent years, we have seen an increasing use of noninvasive ventilation (NIV) in the context of acute respiratory insufficiency (acute respiratory failure). However, adherence to treatment is not perfect; partly because of patient's complaints relating to high-pressure levels. This led to envisaging if the use of lower ventilatory pressures could lead to the same clinical results of the higher pressures, on patients with the restrictive pulmonary disease. We have read with great interest study by Kadowaki et al. published in your journal, entitled “Low-intensity noninvasive ventilation: Lower pressure, more exacerbations of chronic respiratory failure,” presenting a retrospective study where they investigated the effects of lower NIV pressure on chronic respiratory failure. It concluded that patients can develop more exacerbations, recommending the use of higher initial support pressure levels.[1] It is an interesting and original article to read, but we would like to comment some parts of it: First, we do not agree with the nondiscrimination of hypercapnic respiratory insufficiency, being defined only by the value of PaCO2. There is not any reference to the value of oxygen (or pH) and we think that a patient with severe – mild hypoxemia and hypercapnia are surely different from a patient with the only hypercapnia, and this may alter the results because these two subtypes are associated with different outcomes[2] Second, according to the authors, its protocol to start with lower pressure levels (LPLs). We understand that the aim of this work was to study this issue and we also accept this strategy may be an attempt to improve the patients' adherence; however, we do not agree to be standard starting with low inspiratory positive airway pressure (IPAP). Most recent guidelines report that even patients with restrictive disease should start with initial IPAP 15–20 cmH2O[3] Finally, all patients had heated humidifier and its benefits are well known, although it is not unanimous its routine use.[3] There are, however, data in literature showing that advantages are more prominent with higher IPAP pressure level.[4] It is also widely known that use of these devices cause adverse effects such as the risk of infection or poor compliance. Could this have affected patients with LPLs and led to worse outcomes?

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

1.  Efficacy of a heated passover humidifier during noninvasive ventilation: a bench study.

Authors:  Anne E Holland; Linda Denehy; Catherine A Buchan; John W Wilson
Journal:  Respir Care       Date:  2007-01       Impact factor: 2.258

2.  Low-intensity noninvasive ventilation: Lower pressure, more exacerbations of chronic respiratory failure.

Authors:  Toru Kadowaki; Kiryo Wakabayashi; Masahiro Kimura; Kanako Kobayashi; Toshikazu Ikeda; Shuichi Yano
Journal:  Ann Thorac Med       Date:  2016 Apr-Jun       Impact factor: 2.219

Review 3.  Timing of noninvasive ventilation failure: causes, risk factors, and potential remedies.

Authors:  Ezgi Ozyilmaz; Aylin Ozsancak Ugurlu; Stefano Nava
Journal:  BMC Pulm Med       Date:  2014-02-13       Impact factor: 3.317

4.  British Thoracic Society/Intensive Care Society Guideline for the ventilatory management of acute hypercapnic respiratory failure in adults.

Authors:  Craig Davidson; Steve Banham; Mark Elliott; Daniel Kennedy; Colin Gelder; Alastair Glossop; Colin Church; Ben Creagh-Brown; James Dodd; Tim Felton; Bernard Foëx; Leigh Mansfield; Lynn McDonnell; Robert Parker; Caroline Patterson; Milind Sovani; Lynn Thomas
Journal:  BMJ Open Respir Res       Date:  2016-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.